Perimenopause Symptoms: What They Are, Why They Happen, and How to Treat Them

What Actually Happens During Perimenopause

Perimenopause is not a single event. It is a prolonged endocrine shift driven by progressive ovarian follicle depletion, during which estradiol levels become erratic before declining permanently. The hypothalamic-pituitary axis responds by increasing follicle-stimulating hormone (FSH) output in an effort to recruit remaining follicles. Those elevated FSH pulses, combined with the loss of steady estradiol signaling, produce the clinical picture most women recognize as "the change."

The Stages of Reproductive Aging Workshop (STRAW+10) criteria, published in Fertility and Sterility in 2012, define early perimenopause as variable cycle length differing by 7 or more days from the norm, and late perimenopause as 60 or more days of amenorrhea [1]. These criteria remain the reference standard used by the Endocrine Society and the Menopause Society (formerly NAMS) for staging.

Because estradiol receptors are distributed in the brain, cardiovascular system, bone, bladder, vaginal epithelium, and skin, the symptom list extends well beyond the reproductive tract. A 2019 cross-sectional study of 695 midlife women found that the median number of concurrent perimenopause symptoms was 7, with a range reaching 20 or more in the most affected quartile [2]. That breadth explains why a single targeted approach rarely covers every complaint.

Hot Flashes: Causes, Triggers, and Treatment Options

Hot flashes are the hallmark vasomotor symptom of perimenopause. Roughly 80% of women experience them at some point in the transition, and for about 25% they persist for more than 10 years after the final menstrual period [3]. A hot flash is a sudden wave of heat, typically over the chest, neck, and face, lasting 1 to 5 minutes and often followed by sweating and chills. Night sweats are the nocturnal equivalent and directly fragment sleep architecture.

The mechanism centers on the hypothalamic thermoregulatory zone. Declining estradiol appears to narrow the thermoneutral zone, the range of core body temperature within which the hypothalamus does not trigger cooling responses. Even small elevations in core temperature then trip the threshold, causing cutaneous vasodilation and sweating [4]. Kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus mediate this process, which is why the neurokinin 3 receptor antagonist fezolinetant (Veozah) reduces hot flash frequency by targeting that pathway directly.

Evidence-based treatments at a glance:

• Systemic estrogen therapy (with progestogen if the uterus is intact) remains the most effective option. The WHI Memory Study and subsequent analyses confirmed a 75% reduction in moderate-to-severe vasomotor symptom frequency with standard-dose conjugated equine estrogens [5].
• Fezolinetant 45 mg daily: in the SKYLIGHT 1 trial (N=501), hot flash frequency fell by 59% at week 12 versus 40% with placebo (P<0.001) [6]. The FDA approved it in May 2023 for moderate-to-severe vasomotor symptoms in women who cannot or choose not to use hormone therapy.
• Low-dose paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI specifically for vasomotor symptoms; it reduced hot flash frequency by 33-65% in registration trials [7].
• Venlafaxine 75 mg, gabapentin 300 mg three times daily, and oxybutynin 2.5-5 mg twice daily each carry supportive evidence from randomized controlled trials but lack a formal menopause-specific FDA indication.

Lifestyle factors that worsen hot flashes include smoking, BMI above 30, alcohol, caffeine, and warm ambient temperature. Modifying these is reasonable first-line advice, though evidence that modification alone achieves clinically significant relief is limited.

Menopause Insomnia: Why Sleep Suffers and How to Fix It

Sleep disruption affects up to 60% of perimenopausal and postmenopausal women, making it one of the most prevalent and undertreated symptoms of the transition [8]. The causes are layered. Night sweats fragment sleep directly. Declining estradiol and progesterone alter slow-wave and REM sleep architecture independently of temperature. A 2021 analysis of the Study of Women's Health Across the Nation (SWAN) cohort found that women in late perimenopause had objectively measured sleep efficiency roughly 6 percentage points lower than premenopausal controls, even after adjusting for hot flash frequency [9].

Primary insomnia disorder can co-occur with perimenopause and requires its own treatment. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line recommendation from the American Academy of Sleep Medicine regardless of menopausal status [10]. In the context of menopause, however, CBT-I alone may be insufficient when night sweats are the primary driver.

Practical treatment ladder:

1. CBT-I: 6-8 sessions, digital programs (Sleepio, Somryst) show comparable efficacy to in-person delivery.
2. Systemic HRT: corrects the hormonal substrate driving both night sweats and direct sleep architecture changes.
3. Progesterone 200-300 mg oral at bedtime: micronized progesterone has sedating properties via GABA-A receptor activity; the PEPI trial showed improved sleep quality scores compared with placebo [11].
4. Low-dose doxepin 3-6 mg (Silenor): FDA-approved for sleep maintenance insomnia; does not address the hormonal cause but can bridge acute distress.
5. Melatonin 0.5-5 mg: modest evidence for sleep-onset latency reduction; Cochrane review found effect size of 0.22 compared with placebo [12].

Genitourinary Syndrome of Menopause (GSM): Vaginal Dryness and Beyond

GSM is the updated clinical term, established by the International Society for the Study of Women's Sexual Health and the Menopause Society in 2014, replacing the older term "atrophic vaginitis." The change in terminology reflects the recognition that declining estradiol affects not only vaginal tissue but also the urethra, bladder trigone, and pelvic floor.

Prevalence exceeds 50% of postmenopausal women, yet studies consistently show that fewer than 25% of affected women ever discuss it with a clinician [13]. That gap matters because GSM is progressive: without treatment, vaginal pH rises above 5.0, epithelial thickness decreases, and Lactobacillus colonization gives way to diverse polymicrobial flora. The result is a cycle of dryness, irritation, dyspareunia, recurrent urinary tract infections, and urinary urgency that worsens over time.

Unlike vasomotor symptoms, which may remit spontaneously in many women, GSM does not improve without intervention [14].

Treatment options ranked by evidence:

• Local vaginal estrogen (estradiol cream 0.01%, estradiol vaginal ring 2 mg/90 days, or estradiol vaginal tablet 4 mcg/10 mcg) is first-line for isolated GSM. Systemic absorption is minimal at approved doses; the Menopause Society states that low-dose vaginal estrogen is safe for most women, including breast cancer survivors in consultation with their oncologist [15].
• Ospemifene (Osphena) 60 mg oral daily: a selective estrogen receptor modulator approved for moderate-to-severe dyspareunia from GSM. The REJOICE trial (N=632) showed a statistically significant improvement in the Most Bothersome Symptom score at 12 weeks versus placebo [16].
• Prasterone (Intrarosa) 6.5 mg vaginal insert daily: an intravaginal DHEA that converts locally to estradiol and testosterone. Phase 3 data showed significant improvements in vaginal cell maturation index, pH, and dyspareunia at 12 weeks [17].
• OTC vaginal moisturizers (polycarbophil-based, hyaluronic acid): address comfort but do not reverse epithelial atrophy. Appropriate as adjuncts or for women who decline prescription therapy.
• Lubricants (silicone or water-based): for acute use during intercourse only; no disease-modifying effect.

The Menopause Society 2023 position statement specifies: "Low-dose vaginal estrogen products are safe for most women and are recommended as an effective treatment for GSM symptoms, including vaginal dryness, dyspareunia, and urinary urgency" [15].

Mood Changes, Anxiety, and Cognitive Symptoms

Mood disruption in perimenopause is not simply a reaction to poor sleep or bothersome physical symptoms. Estradiol is a neuroactive steroid that modulates serotonin transporter expression, monoamine oxidase activity, and dopaminergic tone. The period of greatest estradiol volatility, early-to-mid perimenopause, corresponds to peak risk for new-onset depressive symptoms.

A longitudinal analysis from the SWAN study found that perimenopausal women had a 1.8-fold higher odds of a CES-D score indicating depressive symptoms compared with premenopausal controls, even after controlling for prior depression history [18]. Women with a prior history of major depressive disorder or postpartum depression face 2-to-4-fold higher risk during perimenopause.

Cognitive complaints, particularly word-finding difficulties and short-term memory lapses, are reported by roughly 60% of perimenopausal women. The Study of Women's Health Across the Nation showed objective processing speed and verbal memory decrements in late perimenopause that partially recovered after menopause, suggesting the transition itself, rather than permanent estrogen loss, drives the effect [19].

Clinical approach:

• Screen using the PHQ-9 and GAD-7 at every perimenopausal visit.
• Systemic HRT may improve mood in perimenopausal women with depressive symptoms, though it is not a standalone antidepressant. A 2018 randomized trial published in JAMA Psychiatry (N=172) found that transdermal estradiol 0.1 mg/day plus micronized progesterone reduced the incidence of clinically significant depressive symptoms by 32% over 12 months versus placebo [20].
• SSRIs and SNRIs remain standard of care for clinical depression and anxiety disorders arising during perimenopause. Co-prescribing with HRT is appropriate when both conditions are present.

Lesser-Known Perimenopause Symptoms Clinicians Often Miss

The symptoms below are less visible in the literature but appear consistently in large epidemiological cohorts and clinical practice.

Heart palpitations. Estradiol modulates cardiac ion channels and autonomic nervous system tone. Palpitations without structural arrhythmia are reported by approximately 25% of perimenopausal women. ECG and cardiac evaluation are warranted before attributing palpitations solely to estrogen withdrawal, but in the absence of pathology, HRT often resolves them.

Joint pain and musculoskeletal symptoms. The SWAN study documented a significant increase in bodily pain scores across the perimenopause transition, independent of BMI or physical activity [21]. Estrogen receptors on chondrocytes and synoviocytes likely mediate this effect.

Skin thinning and hair changes. Estradiol supports dermal collagen synthesis; studies show approximately 30% of collagen content is lost in the first 5 years after menopause [22]. Topical estradiol applied to facial skin has demonstrated collagen improvement in small RCTs, though systemic HRT data are more consistent.

Bladder urgency and recurrent UTIs. Urethral and bladder trigone mucosa are estrogen-sensitive. GSM-related changes raise UTI risk; low-dose vaginal estrogen reduces recurrent UTI frequency by approximately 50% in postmenopausal women per a Cochrane review [23].

Tinnitus, burning mouth, and altered taste. These are less studied but biologically plausible given estrogen receptors in the auditory system and oral mucosa. Clinical trial data remain sparse; they should prompt evaluation to exclude other causes before attributing to perimenopause.

How Perimenopause Is Diagnosed

There is no single blood test that confirms perimenopause. Diagnosis is primarily clinical and based on age, menstrual history, and symptom pattern. The Menopause Society recommends against routine FSH testing in women over 45 with typical symptoms, because FSH fluctuates widely during perimenopause and a single normal value does not exclude the diagnosis [24].

When lab testing adds value:

• Age <45 with suspected early perimenopause or premature ovarian insufficiency (POI): two FSH values above 40 IU/L drawn 4-6 weeks apart, plus estradiol below 50 pg/mL, support the diagnosis.
• Ruling out thyroid dysfunction: TSH is essential because hypothyroidism and hyperthyroidism both produce hot flashes, fatigue, weight change, and mood disruption that mimic perimenopause. A 2020 study in Thyroid found that 14% of women presenting to menopause clinics had an undiagnosed thyroid disorder [25].
• Ruling out pregnancy: FSH elevation alone in the early 40s can coexist with residual fertility.

The STRAW+10 staging system remains the standard framework. An FSH above 10 IU/L on cycle day 2-3, combined with variable cycle length, places a woman in early perimenopause. Sustained amenorrhea for 60 or more days signals late perimenopause. Twelve consecutive months of amenorrhea confirms menopause, at which point FSH is typically above 40 IU/L and estradiol is below 20 pg/mL.

Systemic HRT: Who Should Consider It and When

Systemic hormone therapy remains the most comprehensively effective treatment for perimenopausal symptoms. The "timing hypothesis," derived from re-analysis of the Women's Health Initiative and confirmed in the ELITE trial (N=643, mean follow-up 5 years), holds that cardiovascular risk profile differs significantly by how soon after menopause therapy is initiated [26]. Women who start HRT within 10 years of their final menstrual period or before age 60 show neutral to favorable cardiovascular outcomes. Women who start more than 10 years after menopause or past age 60 face a modestly elevated risk.

The Menopause Society 2022 position statement concludes: "For women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [27].

Contraindications to systemic estrogen include unexplained vaginal bleeding, active or recent breast cancer, active thromboembolic disease, and active liver disease. Women with a uterus require progestogen (either synthetic progestin or micronized progesterone) added to estrogen to protect against endometrial hyperplasia.

Transdermal delivery avoids first-pass hepatic metabolism and carries a lower venous thromboembolism risk compared with oral estrogen; a large UK case-control study (N=80,396) found that transdermal estradiol was not associated with increased VTE risk, while oral estrogen was associated with an approximately 58% relative risk increase [28].

Monitoring and Follow-Up Once Treatment Begins

Women initiating HRT for perimenopause symptoms should have a follow-up visit at 6-12 weeks to assess symptom response and side effects, then annually thereafter. The annual review should include:

• Blood pressure measurement.
• Breast exam and mammography per age-appropriate screening schedules (annual mammography from age 40 per the American College of Radiology).
• Reassessment of continued indication: vasomotor symptoms resolve in some women after 2-3 years; others require therapy for a decade or longer.
• Bone density (DEXA) at menopause confirmation, then every 2 years in women with risk factors.

There is no mandated maximum duration of HRT. The decision to continue should be individualized based on ongoing symptom burden, cardiovascular risk, breast density, and personal preference. A 2023 retrospective cohort study in the BMJ (N=98,775) found no significant increase in all-cause mortality among women who used HRT for more than 10 years when therapy was initiated before age 60 [29].

Stopping HRT abruptly can cause recurrence of vasomotor symptoms in up to 50% of women; a gradual taper over 3-6 months reduces rebound hot flash frequency compared with abrupt discontinuation.